Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      botox
      LOZENGE BOTOX 2 part 1
      LOZENGE BOTOX 2 part 2

      +30 years of global experience across multiple conditions1-4

      CHRONIC MIGRAINE*

      A debilitating disease affecting 1.4-2.2% of adults globally.5,6 Explore chronic migraine from the patient's perspective, and learn about how BOTOX® could positively impact your patients' lives7,8

      CHRONIC MIGRAINE

      UROLOGY†

      Having overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) can impact your patient's quality of life when left untreated.9 Learn about the impact on patients and how BOTOX® can alleviate symptoms of OAB and NDO10

      OVERACTIVE BLADDER (OAB)
      NEUROGENIC DETRUSOR OVERACTIVITY (NDO)

      FOCAL SPASTICITY‡

      Spasticity is a common consequence of neurological disorders such as stroke and can have a substantial effect on a patient's ability to undertake basic everyday tasks.11 Learn about the importance of early identification12 and the potential benefits BOTOX® could offer10

      FOCAL SPASTICITY
      botox
      LOZENGE BOTOX 2 part 1 mobile
      LOZENGE BOTOX 2 part 2 mobile

      +30 years of global experience across multiple conditions1-4

      CHRONIC MIGRAINE*

      A debilitating disease affecting 1.4-2.2% of adults globally.5,6 Explore chronic migraine from the patient's perspective, and learn about how BOTOX® could positively impact your patients' lives7,8

      CHRONIC MIGRAINE

      UROLOGY†

      Having overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) can impact your patient's quality of life when left untreated.9 Learn about the impact on patients and how BOTOX® can alleviate symptoms of OAB and NDO10

      OVERACTIVE BLADDER (OAB)
      NEUROGENIC DETRUSOR OVERACTIVITY (NDO)

      FOCAL SPASTICITY‡

      Spasticity is a common consequence of neurological disorders such as stroke and can have a substantial effect on a patient's ability to undertake basic everyday tasks.11 Learn about the importance of early identification12 and the potential benefits BOTOX® could offer10

      FOCAL SPASTICITY

       

      BOTOX® has an efficacy and tolerability profile from
      +30 years of global use in a range of conditions2-4

      Explore the licensed indications timeline1

      First approved by the US FDA in 198913 and 25 years of experience in the UK1

      Year pic01

      UK approval:

      blepharospasm and hemifacial spasm1

      Year pic02

      UK approval:

      idiopathic cervical dystonia1

      UK approval:

      juvenile cerebral palsy1

      Year pic04

      UK approval:

      axillary hyperhidrosis1

      Year pic05

      UK approval:

      post-stroke wrist and hand spasticity1

      Year pic06

      UK approval:

      chronic migraine1

      Year pic07

      UK approval:

      neurogenic detrusor overactivity1

      Year pic08

      UK approval:

      overactive bladder1

      Year pic09

      UK approval:

      post-stroke ankle spasticity1

      Year pic10

      UK approval:

      post-stroke ankle and foot spasticity1

      Year pic11

      UK approval:

      ankle and foot spasticity in paediatric cerebral palsy1

      Year pic12

      UK approval:

      elbow, wrist and hand in paediatric cerebral palsy1

      Year pic13

      UK approval:

      upper and lower limb spasticity1

      Previous
      Next

      *BOTOX® is indicated for prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).10

      †BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.10

      ‡BOTOX® is indicated for the symptomatic treatment of focal spasticity, including: elbow, wrist and hand in paediatric cerebral palsy patients and ankle and foot in ambulant paediatric cerebral palsy patients, two years of age or older as an adjunct to rehabilitative therapy; upper limb spasticity in adults and ankle and foot disability due to lower limb spasticity in adults.10

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      6. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      7. Dodick D W, Turkel C C et al. Onabotulinum toxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936
      8. Khalil M, Zafar H W et al. Prospective analysis of the use of onabotulinum toxin A (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54
      9. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      10. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed April 2024
      11. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines, 20 March 2018. Available at: https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin. Accessed April 2024 
      12. Glaess-Leistner S, Ri S J et al. Early clinical predictors of post-stroke spasticity. Top Stroke Rehabil. 2020:1-11
      13. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      6. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      7. Dodick D W, Turkel C C et al. Onabotulinum toxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936
      8. Khalil M, Zafar H W et al. Prospective analysis of the use of onabotulinum toxin A (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54
      9. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      10. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc /product/859/smpc. Accessed April 2024
      11. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines, 20 March 2018. Available at: https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin. Accessed April 2024 
      12. Glaess-Leistner S, Ri S J et al. Early clinical predictors of post-stroke spasticity. Top Stroke Rehabil. 2020:1-11
      13. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: May 2024. UK-BTX-240020.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.